AI-generated illustration; not a photograph of the reported event.
- calendar_today October 22, 2026
Chemotherapy Drug Shortage Strains Health Systems
A nationwide shortage of the generic chemotherapy drug ifosfamide is having a significant impact on Indiana’s healthcare systems and hospitals across the United States. Access to this medication is critical for cancer patients who rely on it as part of treatment regimens designed to maximize cure rates. The current shortage has forced changes to established treatment plans and introduced uncertainty for many patients and providers.
Cancer Patients Face Treatment Delays and Uncertainty
Myron Howe, who is fighting testicular cancer, is currently hospitalized in Maryland while waiting for access to ifosfamide. Howe explained that his cure rate was originally as high as 85%, but due to the drug’s unavailability, it has dropped to 40%. He described the emotional and physical strain caused by treatment delays, as well as the additional complications from cancer spreading to his organs.
Scope of the Ifosfamide Shortage
Ifosfamide is used to treat a variety of cancers, including testicular, bladder, ovarian, severe adult and pediatric leukemias, and lymphomas. The shortage is attributed to a manufacturing problem overseas. According to the National Comprehensive Cancer Network (NCCN), every hospital system in the U.S. currently reports lacking one or more crucial cancer medications.
Dr. Nabil Adra, Medical Director for Clinical Operations at the IU Health Simon Cancer Center, said Indiana has faced challenges due to the ifosfamide shortage for several months. At one point, Indiana hospitals had just a few weeks’ supply and had to prioritize availability for patients most likely to be cured with the drug. While the situation has somewhat improved, Adra noted that the shortage remains an ongoing issue.
Healthcare System Response and Drug Prioritization
The IU Simon Comprehensive Cancer Center and the IU Health System Cancer Institute responded to the ifosfamide shortage by implementing a contingency plan. A system-wide committee involving physicians, pharmacists, and ethics specialists meets weekly to review each patient’s request for ifosfamide, establishing a prioritization list to allocate the limited drug supply based on urgency and potential benefit.
Dr. Adra indicated that while Indiana's supply outlook has improved since the most acute phase of the shortage, vigilance and active management continue to be necessary to address daily needs.
Underlying Causes and National Perspective
The root of the ifosfamide shortage lies in manufacturing disruptions. The European Medicines Agency reported that in September 2025, a technical problem at a manufacturing plant in Germany led to a regulatory suspension and halted production. While manufacturing has since resumed, the temporary pause caused a ripple effect through the drug’s supply chain.
Alyssa Schatz, DrPh, MSW, Vice President of Policy & Advocacy at NCCN, explained that cancer medication shortages have persisted for years due to challenges in the supply chain of generic drugs. With generic medications operating on slim margins and limited manufacturers, any disruption—whether from a failed inspection or a natural disaster—can significantly impact availability.
Future Outlook for Ifosfamide Supply
The IU Health System expects improved access to ifosfamide beginning in November. "We’re expecting improvement in supply in November, and this continues to improve," said Dr. Adra, expressing cautious optimism that the shortage may not persist much longer, though the situation continues to require careful management.
In the meantime, cancer patients, physicians, and hospitals continue to navigate the challenges caused by the ifosfamide shortage, advocating for a more resilient drug supply chain and effective solutions to prevent similar disruptions in the future.
Source: fox59.com.
